Status:
UNKNOWN
[68Ga] NOTA-SGC8 in the Staging of Bladder Cancer
Lead Sponsor:
RenJi Hospital
Conditions:
Bladder Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to test the imaging and diagnostic ability of \[68Ga\]-NOTA-SGC8 PET/MR in bladder cancer patients with different stages. The main questions it aims to answer are: ...
Detailed Description
Participants will be irrigated with \[68Ga\]-NOTA-SGC8 intravesically, with 0.05mCi/kg per person per time according to body weight, no more than 5mCi. The participants will be instructed to urinate c...
Eligibility Criteria
Inclusion
- Patients with newly diagnosed or previously diagnosed bladder tumors.
- At least one cystoscopy was performed within one month prior to enrollment, and the clinical diagnosis of bladder tumor was present.
- Age \> 18 years, \< 80 years
- Patients voluntarily participate and sign informed consent and are willing and able to follow protocol requirements.
Exclusion
- Pregnancy, lactation, severe liver and kidney insufficiency and children;
- Participants who are allergic to the experimental drug, have an allergic disposition, or are allergic to multiple drugs.
Key Trial Info
Start Date :
September 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06005116
Start Date
September 15 2023
End Date
December 31 2024
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital
Shanghai, Shanghai Municipality, China, 200127